Find Out About Pre-Exposure Prophylaxis (PrEP) Funding Opportunities
Non-dilutive funding for approaches to predicting treatment-responsive patients to enable therapeutic efficacy of BARDA medical countermeasure products for national health security.
Applications for 2025 are now closed. Schedule a call to find out more about future opportunities.
VITAL and BARDA are seeking technologies and approaches that can predict and enable treatment benefit among patients for new or existing therapeutics that treat CBRN (chemical, biological, radiological or nuclear) threats, injuries, insults, infection or severe disease from other health security threats.
Context and Background
Variability in treatment effect across patients has consistently been observed. In some fields, like oncology, companion and complementary diagnostics have been developed to drive patient subtyping approaches to inform who will benefit from specific therapeutics. There is interest in now applying these strategies to other scenarios, like critical care, relevant to BARDA’s mission space. Such approaches may enable therapeutic efficacy in clinical trials and guide therapeutic use after market approval.
As part of BARDA DRIVe’s Type to Treat Program, this funding opportunity aims to leverage such strategies to support clinical use of FDA-approved medical countermeasures or development of new therapeutics relevant to BARDA’s mission space – CBRN threats, pandemic influenza, and emerging infectious diseases.
VITAL and BARDA seek technologies and approaches that can predict treatment benefit among patients to increase the probability of demonstrating therapeutic efficacy during clinical development and to guide treatment decisions during clinical care for improved patient outcomes. These technologies may be based on phenotyping, sub-phenotyping, endotyping, genotyping, and/or other approaches to identify patients likely to benefit from specific treatments. Example technologies may include but are not limited to assays, lab tests, and software as medical devices.
Funding Guidelines & Duration
Pre-proposal applications are now closed. Stay tuned for additional funding programs!
Applicants advancing to the next stage will be notified in November 2025 to submit a full application for this cycle (by invitation only).
Awardees will be selected and notified in early 2026.
Watch our info session to gain insights into the VITAL Non-Dilutive Funding Opportunities and Programs
Join one of our live webinars by signing up to a session here.
Online Webinar
Join us for one of our info sessions to answer all your questions about Funding Opportunities and Programs made available through the VITAL Hub. This session is perfect for innovators, entrepreneurs, and biotech startups pioneering the future of innovative therapeutics solutions.
If you or your organization would like to explore collaborations with other potential applicants, please visit our TyPe Teaming Page.
Applications will be reviewed in whole based on responses to the questions in the application and all information submitted, with focus on alignment to the program requirements and program strategy, innovation and quality of data presented, technical approach and milestones to be achieved with the proposal, team and resources available, ability to transition and commercialize the product, and cost/price reasonableness for the proposed use of funds.
The TyPe awards are anticipated to be multi-year awards for development activities taking approximately 1-3 years; however the exact timeline for each project will be finalized during negotiations.
There will be reporting requirements on a monthly or quarterly basis, annual reports, and final reports. The applicant and VITAL will agree during negotiations and before final award which standard reporting requirements and other deliverables are necessary as determined by the final, mutually agreed-upon Statement of Work, project deliverables.
No. SAM.gov registration is not required.
This funding opportunity does not support gain of function research or research that involves the manipulation of pathogens resulting in potential gain of function.
Proposals will be evaluated for the appropriate use of strain(s) in proposed studies.
